Guest Bio for this week: Dr. Stephen Bright
Dr. Stephen Bright is a leading voice on psychedelic research and drug policy in Australia.
Stephen is a clinically-trained psychologist, though he identifies as an ethnopharmacologist (i.e, a person who studies the human relationship with drugs). He is a leading Australian voice on the role of drug policy on emerging drug trends such as synthetic cannabis and darkweb marketplaces.
0:00-3:09: Welcome, opening remarks, Dr. Stephen Bright’s bio.
3:09-7:10: Steve’s background in psychedelic research
7:10-12:45: How MDMA & other psychedelics can help treat trauma
12:45-18:42: Psychedelics (Entheogens) & Spiritual Experiences
18:42-23:23: Integrating psychedelic experiences
23:23-34:23: What distinguishes MDMA from other psychedelics
34:23-40:10: Obstacles to psychedelic research in Australia
40:10-47:05: Consideration of the relative toxicity of alcohol, psychedelics and opiates
47:05-51:14: Upcoming events and contact info for Dr. Bright
How to find Dr. Stephen Bright
Please help to make Hacking the Self a sustainable project by:
- Making a donation at https://www.patreon.com/hackingtheself
You can also help us to get the word out by:
- Sharing this interview with friends and on your social media platforms
- Writing a review for the podcast on iTunes, Sticher or the Google Music Store
Thank you for the podcast. There’s no reason for Australia to fall behind, once the health officials hear and understand the research, they would gladly welcome it in, I suppose we should be clarifying who these individuals are and organising meeting with them to share that information.
In regards to getting the right balance Adrian, I think delving into the deep is where it gets juicy, and the juiciness is appreciated by beginners and experts alike!
Thanks for sharing Chris. I appreciate you offering your thoughts and I agree there’s absolutely no reason for Australia to fall behind. Let’s hope that the good efforts of Dr. Bright, PRISM and others bear fruit for the many people who deserve access to these treatments in Australia.